Skip to main content
SpringerLink
Log in

Therapeutic Drug Monitoring of Antidementia Drugs: A Valid Tool for Successful Individual Benefit/Risk Evaluation

  • Abstract
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry 2004; 37: 243–65

    Article  PubMed  CAS  Google Scholar 

  2. Haen E, Greiner C, Bader W, et al. Wirkstoffkonzentrationsbestimmungen zur Therapieleitung: Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche. Nervenarzt 2008; 79: 558–66

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology/Psychopharmacology, Department of Psychiatry and Psychotherapy, University ofc Regensburg School of Medicine, Regensburg, Germany

    R. Koeber, D. Melchner & E. Haen

  2. Clinical Neuropsychiatric Genetics, Department of Psychiatry and Psychotherapy, University of Regensburg School of Medicine, Regensburg, Germany

    H. H. Kluenemann

Authors
  1. R. Koeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. H. Kluenemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Melchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Haen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koeber, R., Kluenemann, H.H., Melchner, D. et al. Therapeutic Drug Monitoring of Antidementia Drugs: A Valid Tool for Successful Individual Benefit/Risk Evaluation. Drug-Safety 31, 885 (2008). https://doi.org/10.2165/00002018-200831100-00047

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831100-00047

Keywords

Search

Navigation